Cervical cancer
Drug research and approvals for cervical cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,898 studies of cervical cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 20 drug trials for it since 2013, FDA has 0 approved and 8 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 1,898
- Trials authorized in Canada: 20
- FDA orphan approvals: 0
- EU medicines: 1
- KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical…NCT07948083 · Phase 1 / Phase 2 · Wuhan KadGeno Biotechnology Co., Ltd · starts Jan 6, 2026
- Compressive Dressing and Pharyngocutaneous Fistula After Primary Total LaryngectomyNCT07949526 · Not reported · IRCCS San Raffaele · starts May 5, 2025
- Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) InjectionNCT07947043 · Phase 1 · Tongji Hospital · starts Apr 22, 2025
- APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III…NCT07944547 · Not applicable · Xiangya Hospital of Central South University · starts May 26, 2025
- Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA)NCT07938385 · Not reported · Royal Marsden NHS Foundation Trust · starts May 20, 2022
- Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor BoardsNCT07939139 · Not reported · Technical University of Munich · starts Nov 9, 2026
- A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal…NCT07925021 · Phase 3 · CSPC Megalith Biopharmaceutical Co.,Ltd. · starts Nov 6, 2026
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07925307 · Not applicable · University of California, San Diego · starts Oct 16, 2026
- Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single…NCT07922967 · Not reported · Oslo University Hospital · starts Nov 20, 2026
How its trials ended
1,523 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 245 whose ending is known, 36% met their primary endpoint, 7% missed it and 58% stopped early.
- Completed, result not reported52735%
- Ongoing46931%
- Status unknown28219%
- Met its primary endpoint876%
- Stopped: other or unclear765%
- Stopped: enrollment or feasibility382%
- Missed its primary endpoint171%
- Stopped: sponsor or business decision141%
- Stopped: funding7<1%
- Stopped: lack of efficacy3<1%
- Stopped: safety3<1%
| Oct 17, 2025 | A phase 3, randomized, open-label, multicenter study to evaluate the efficacy and safety of sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab…MK-2870 [sacituzumab tirumotecan (SKB264)] / Keytruda [MK-3475 (pembrolizumab)]… | Merck & Co. (MSD) | Ongoing |
| Jun 13, 2024 | A phase 3 randomized, active-controlled, open-label, multicenter study to compare the efficacy and safety of MK-2870 monotherapy versus treatment of…MK-2870 (SKB264) | Merck & Co. (MSD) | Ongoing |
| May 30, 2024 | Beamion pantumor-1: a phase II, multicentre, multicohort, open label trial to evaluate the efficacy and safety of oral zongertinib (bi 1810631) for the…Zongertinib (bi 1810631) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Jul 12, 2023 | A phase III, randomized, double blind, placebo controlled, multi centre, global study of volrustomig in women with high risk locally advanced cervical cancer…Volrustomig (MEDI5752) | AstraZeneca Pharmaceuticals | Ongoing |
| Apr 28, 2021 | A randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage…Triapine | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Closed |
| Feb 3, 2021 | A randomized, open-label, phase 3 trial of tisotumab vedotin vs investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical…Tisotumab vedotin | Pfizer | Ongoing |
| Apr 23, 2020 | A phase II, safety, and efficacy study of tiragolumab plus atezolizumab and atezolizumab monotherapy in patients with metastatic and/or recurrent…Tiragolumab (RO7092284) / Tecentriq (atezolizumab) | Roche | Ongoing |
| Feb 17, 2020 | A randomized, phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer…Keytruda (pembrolizumab) | Merck & Co. (MSD) | Ongoing |
| Jul 15, 2019 | Figo 2018 stage IB2 (>2cm - <4 cm) cervical cancer treated with neoadjuvant chemotherapyCisplatin/ Carboplatin/ Paclitaxel | Princess Margaret Cancer Centre | Ongoing |
| Apr 29, 2019 | Image guided intensity modulated external beam radiochemotherapy and MRI based adaptive brachytherapy in locally advanced cervical cancerGlucovision | Princess Margaret Cancer Centre | Pending |
| Aug 19, 2021 | Cemiplimab-rwlcTreatment of stage IA2 to stage IV cervical cancer | Regeneron Pharmaceuticals, Inc. | Designated |
| Feb 18, 2021 | Recombinant bispecific humanized anti-programmed cell death…Treatment of Stage IA2-IV cervical cancer | Akeso Biopharma, Inc. | Designated |
| Dec 1, 2020 | Human autologous CD4+ and CD8+ T cells engineered ex vivo…Treatment of patients with human papillomavirus (HPV)+ cervical cancer who are human leukocyte antigen (HLA)-A*02+ | Kite Pharma, Inc. | Designated |
| Jun 26, 2020 | A therapeutic vaccine targeting the HPV16 E6/E7 proteinsTreatment of HPV16-positive cervical cancer | ISA Therapeutics BV | Designated |
| Apr 30, 2018 | Autologous tumor infiltrating lymphocytes (TIL)Treatment of cervical cancer with a tumor size greater than 2 cm. in diameter | Iovance Biotherapeutics, Inc. | Designated |
| Nov 8, 2017 | 3-aminopyridine-2-carboxaldehyde thiosemicarbazoneTreatment of stage 1B to IV cervical cancer | National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD) | Designated |
| Mar 13, 1997 | PorfiromycinTreatment of cervical cancer. | Boehringer Ingelheim Pharmaceuticals, Inc. | Designated |
| Aug 24, 1994 | Recombinant vaccinia (human papillomavirus)Treatment of cervical cancer. | Xenova Research Limited | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Mar 28, 2025 | TivdakTisotumab vedotin | Genmab A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA